
"Promising Trial of First Dengue Fever Prevention Pill Amid Growing U.S. Fears"
Johnson & Johnson has presented promising data on an antiviral pill, JNJ-1802, that appears to protect against dengue fever in a clinical trial. The trial involved healthy volunteers who were exposed to a type of dengue virus after taking the drug or a placebo. While all participants in the placebo group showed signs of infection, six out of ten participants receiving a high dose of the drug showed no signs of infection. The results offer hope for a future treatment against dengue, a growing health threat worldwide. Johnson & Johnson plans to conduct larger tests and is currently running a Phase 2 clinical trial in ten countries to assess the drug's ability to prevent dengue from all four strains of the virus.

